Your browser doesn't support javascript.
loading
Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population.
Ahmadzada, Tamkin; Cooper, Wendy A; Holmes, Mikaela; Mahar, Annabelle; Westman, Helen; Gill, Anthony J; Nordman, Ina; Yip, Po Yee; Pal, Abhijit; Zielinski, Rob; Pavlakis, Nick; Nagrial, Adnan; Daneshvar, Dariush; Brungs, Daniel; Karikios, Deme; Aleksova, Vesna; Burn, Juliet; Asher, Rebecca; Grau, Georges E; Hosseini-Beheshti, Elham; Reid, Glen; Clarke, Stephen; Kao, Steven.
Affiliation
  • Ahmadzada T; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
  • Cooper WA; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
  • Holmes M; Tissue Pathology and Diagnostic Oncology, New South Wales Health Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
  • Mahar A; School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.
  • Westman H; Tissue Pathology and Diagnostic Oncology, New South Wales Health Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
  • Gill AJ; Tissue Pathology and Diagnostic Oncology, New South Wales Health Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
  • Nordman I; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Yip PY; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
  • Pal A; Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Zielinski R; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.
  • Pavlakis N; School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
  • Nagrial A; Department of Medical Oncology, Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia.
  • Daneshvar D; School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.
  • Brungs D; School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.
  • Karikios D; Drug Development Unit, Royal Marsden Hospital, Sutton, United Kingdom.
  • Aleksova V; Central West Cancer Care Centre, Orange Base Hospital, Orange, New South Wales, Australia.
  • Burn J; School of Medicine, Western Sydney University, New South Wales, Australia.
  • Asher R; Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Grau GE; Department of Medical Oncology, Royal North Shore Hospital, The University of Sydney, Sydney, New South Wales, Australia.
  • Hosseini-Beheshti E; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
  • Reid G; Medical Oncology Department, Westmead Hospital, New South Wales, Australia.
  • Clarke S; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
  • Kao S; Department of Tissue Pathology and Diagnostic Oncology, Institute of Clinical Pathology & Medical Research (ICPMR)-Westmead Hospital, Sydney, New South Wales, Australia.
JTO Clin Res Rep ; 1(4): 100075, 2020 Nov.
Article in En | MEDLINE | ID: mdl-34589956
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: JTO Clin Res Rep Year: 2020 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: JTO Clin Res Rep Year: 2020 Document type: Article Affiliation country: Country of publication: